Full metadata record

DC Field Value Language
dc.contributor.authorEl-Deeb, Ibrahim M.-
dc.contributor.authorPark, Byung Sun-
dc.contributor.authorJung, Su Jin-
dc.contributor.authorYoo, Kyung Ho-
dc.contributor.authorOh, Chang-Hyun-
dc.contributor.authorCho, Seung Joo-
dc.contributor.authorHan, Dong Keun-
dc.contributor.authorLee, Jae Yeol-
dc.contributor.authorLee, So Ha-
dc.date.accessioned2024-01-20T20:32:21Z-
dc.date.available2024-01-20T20:32:21Z-
dc.date.created2021-09-01-
dc.date.issued2009-10-01-
dc.identifier.issn0960-894X-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/132043-
dc.description.abstractA series of rationally designed ROS1 tyrosine kinase inhibitors was synthesized and screened. Compound 12b has showed good potency with IC50 value of 209 nM, which is comparable with that of the reference lead compound 1. Molecular modeling studies have been performed, that is, a homology model for ROS1 was built, and the screened inhibitors were docked into its major identified binding site. The docked poses along with the activity data have revealed a group of the essential features for activity. Overall, simplification of the lead compound 1 into compound 12b has maintained the activity, while facilitated the synthetic advantages. A molecular interaction model for ROS1 kinase and inhibitors has been proposed. (C) 2009 Elsevier Ltd. All rights reserved.-
dc.languageEnglish-
dc.publisherPergamon Press Ltd.-
dc.subjectC-ROS-
dc.subjectBIOLOGICAL EVALUATION-
dc.subjectGENE-MUTATIONS-
dc.subjectGLIOBLASTOMA-
dc.subjectCANCER-
dc.subjectEXPRESSION-
dc.subjectPATHWAYS-
dc.subjectPOTENT-
dc.titleDesign, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors-
dc.typeArticle-
dc.identifier.doi10.1016/j.bmcl.2009.08.029-
dc.description.journalClass1-
dc.identifier.bibliographicCitationBioorganic & Medicinal Chemistry Letters, v.19, no.19, pp.5622 - 5626-
dc.citation.titleBioorganic & Medicinal Chemistry Letters-
dc.citation.volume19-
dc.citation.number19-
dc.citation.startPage5622-
dc.citation.endPage5626-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000270106700022-
dc.identifier.scopusid2-s2.0-69949108857-
dc.relation.journalWebOfScienceCategoryChemistry, Medicinal-
dc.relation.journalWebOfScienceCategoryChemistry, Organic-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.relation.journalResearchAreaChemistry-
dc.type.docTypeArticle-
dc.subject.keywordPlusC-ROS-
dc.subject.keywordPlusBIOLOGICAL EVALUATION-
dc.subject.keywordPlusGENE-MUTATIONS-
dc.subject.keywordPlusGLIOBLASTOMA-
dc.subject.keywordPlusCANCER-
dc.subject.keywordPlusEXPRESSION-
dc.subject.keywordPlusPATHWAYS-
dc.subject.keywordPlusPOTENT-
dc.subject.keywordAuthorKinase inhibitors-
dc.subject.keywordAuthorROS1-
dc.subject.keywordAuthorGlioblastoma multiforme-
dc.subject.keywordAuthorHomology modeling-
dc.subject.keywordAuthorPyrazole-
Appears in Collections:
KIST Article > 2009
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE